• RxSight filed an amended Form 8-K/A to update disclosures related to the appointment of Chief Financial Officer Mark Wilterding.
• The amendment added compensation information stating Wilterding’s sign-on bonus was determined to be USD 169,348.1 and was paid on March 13, 2026.
• It also corrected the vesting schedule for his stock option, with 25% vesting on the one-year anniversary of January 11, 2026.
• The remaining option shares are scheduled to vest monthly over the following three years, subject to continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RxSight Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-115965), on March 19, 2026, and is solely responsible for the information contained therein.